Reducing Wegovy from 1.7 mg to a Lower Dose for Weight Maintenance
No, you should not routinely reduce Wegovy from 1.7 mg to a lower dose for weight maintenance, as evidence consistently shows significant weight regain occurs with dose reduction or discontinuation. 1
The Evidence Against Dose Reduction
The STEP 4 trial provides the clearest evidence: when patients who achieved weight loss on semaglutide were transitioned to placebo (essentially stopping the medication), they regained 6.9% of their lost weight over 48 weeks. Even more concerning, patients followed for 52 weeks after completing treatment regained 11.6% of their lost weight 1. These data demonstrate that semaglutide must be continued long-term to maintain weight loss benefits.
The 2023 JAMA guidelines explicitly state that "patients should be counseled that antiobesity medications must be used in conjunction with lifestyle changes and may need to be used lifelong" 1. This reflects the biological reality that obesity is a chronic disease requiring ongoing pharmacotherapy.
FDA-Approved Maintenance Dosing
The FDA label for Wegovy is unambiguous: the maintenance dosage in adults is either 2.4 mg (recommended) or 1.7 mg once weekly 2. Importantly, 1.7 mg is already considered a maintenance dose option—not an escalation dose. The label states you should "consider treatment response and tolerability when selecting the maintenance dosage" 2.
If a patient cannot tolerate 2.4 mg, reducing to 1.7 mg is acceptable. However, reducing below 1.7 mg is not FDA-approved for maintenance therapy 2.
When Dose Reduction Might Be Considered (With Caveats)
While not standard practice, emerging real-world data suggests some nuanced scenarios:
Reduced-Frequency Dosing (Not Lower Doses)
One 2026 case series found that patients who achieved weight plateau on weekly semaglutide or tirzepatide maintained their weight loss when switched to reduced-frequency dosing (every other week) at their existing dose 3. Weight actually continued to decline slightly (from 74.1 kg to 72.4 kg, p<0.01), and metabolic improvements were preserved over 36 weeks 3.
This is fundamentally different from reducing the dose—patients maintained the same mg amount but injected less frequently.
Lower Doses in Specific Populations
Real-world studies show some patients achieve meaningful weight loss with submaximal doses:
- Chinese adults with obesity lost 9.9% body weight at 24 weeks on 0.5-1.0 mg maintenance doses 4
- A Danish digital clinic study showed 16.7% weight loss at 64 weeks with mean dose of only 1.08 mg/week 5
- Another Danish primary care study found 13.6% weight loss at 12 months, though 40% of continuing patients used ≤1.0 mg/week 6
However, these studies have critical limitations: they describe what happened in uncontrolled settings, not what should be recommended. The AGA guidelines acknowledge that "some patients may achieve a strong response at a submaximal dose and could continue that given dose long term" 7, but this is expert opinion, not evidence-based guidance for intentional dose reduction after achieving weight loss.
The Clinical Algorithm
For a patient currently on 1.7 mg who has achieved weight loss:
If tolerating well: Continue 1.7 mg indefinitely or escalate to 2.4 mg (the recommended maintenance dose) 2
If experiencing intolerable side effects on 1.7 mg: This is the ONLY FDA-approved scenario for dose reduction—and only in pediatric patients, where you can reduce from 2.4 mg to 1.7 mg 2. In adults, if 1.7 mg is intolerable, discontinuation is recommended rather than further dose reduction 2
If concerned about cost/access: Consider reduced-frequency dosing (e.g., every 10-14 days) at the same 1.7 mg dose, based on emerging evidence 3, though this is off-label
Never reduce below 1.7 mg with the expectation of maintaining weight loss—this contradicts both FDA labeling and clinical trial evidence
Critical Pitfalls to Avoid
Don't confuse dose titration with maintenance: The 0.25 mg, 0.5 mg, and 1.0 mg doses are escalation doses designed to minimize GI side effects, not maintenance options 7, 2
Don't assume weight maintenance is possible off medication: The biological drive to regain weight is powerful and persistent 1
Don't reduce dose simply because weight has plateaued: Weight plateau is expected and doesn't indicate the medication has stopped working—it's preventing weight regain 3
Remember cardiovascular benefits require ongoing therapy: The SELECT trial showed cardiovascular risk reduction with semaglutide 2.4 mg in patients with CVD (HR 0.80,95% CI 0.72-0.90) 1—these benefits would be lost with discontinuation or significant dose reduction
The Bottom Line
Maintain the 1.7 mg dose or escalate to 2.4 mg. The evidence overwhelmingly supports continuous, long-term therapy at FDA-approved maintenance doses. Weight regain is not a matter of "if" but "when" after dose reduction or discontinuation. If cost or tolerability are concerns, explore reduced-frequency dosing at the same dose or consider alternative medications, but do not reduce below 1.7 mg expecting to maintain weight loss.